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1. ABSTRACT
Thymulin (formerly called "Facteur Thymique Sdrique or FTS) is a metallopeptidic hormone
selectively produced by thymic epithelial cells (TEC) and known to induce intra and extra-thymic T
cell differentiation. It was initially isolated.from porcine serum and shown to be present in calf thymus
extract. Its amino-acid sequence was determined (<Glu-Ala-Lys-Ser-GIn-Gly-Gly-Ser-Asn). It is a
nonapeptide whose biological activity is dependent on the presence of zinc, in an equimolecular
ratio. The metallopeptide thus formed bears a specific tridimensional conformation detected by
nuclear magnetic resonance studies, and that yielded a new monoclonal antibody-defined epitope.
The presence of zinc and metallothionein has been demonstrated within TEC which produce the
peptide, suggesting that the molecule is secreted in its active zinc-containing form. The
zinc/thymulin relationship, was further studied using various models of mild zinc deficiency in
experimental animals and in humans. Serum thymulin activity was decreased as a result of zinc
deficiency, and was corrected by in vivo and in vitro zinc supplementation, suggesting that this
parameter could be a sensitive indicator of zinc deficiency. When considered together with the
parallel variations seen in T-cell subpopulations and lymphokine production, these observations
could provide a possible explanation of the role of zinc on T cell functions.
2. INTRODUCTION
It is now widely accepted that the trace element zinc exerts a powerful and apparently
specific influence on the thymus, on T lymphocytes and on cellular immunity, resulting in a strong
immune modulatory activity on cell-mediated responses, in both human and animal systems (1,2).
It is apparent that zinc deficiency severely depresses immune responses. Experimental
zinc deprivation (with all other nutritional elements at a normal level) leads to generalized lymphoid
hypoplasia, rapid thymic involution, particularly of the cortex, decreased production of thymic
hormones, impaired lymphocyte proliferative capacity after phytomitogen stimulation and reduced
antibody and cell-mediated responses.
It thus appears quite clear that zinc deficiency has multiple consequences on the immune
system and that they are similar to those observed after thymectomy, either neonatal thymectomy in
extreme cases of deficiency where zinc deprivation is total and occurs very early, or thymectomy in
the young adult when deficiency is induced during adulthood (3).
Various mechanisms can explain the early thymic atrophy observed in zinc-deprived mice.
Rapidly replicating lymphocytes in the thymus could be particularly sensitive to the functional
anomaly of zinc-rich metalloenzymes required for lymphocyte proliferation. Another hypothesis is
that the epithelial function of the thymus could be specifically altered (4,5). A third involves direct
action of thymulin, a thymic hormone molecule. Several authors have reported that the serum level
of thymulin was abnormally decreased in zinc deficiency, both in the mouse and in man (5,6).
Data from our laboratory favored the view that thymulin was directly dependent on zinc, a
finding which could explain many of the observations reported above. In the present review, we
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shall summarize the data which have appeared in the last few years concerning the relationship
between zinc and thymulin analysed both biochemically and biologically, as well as the alteraction
occurring in some animal and human zinc deficiencies.
3. ZINC/THYMULIN INTERACTIONS
3.1. Biochemical aspects
Thymulin is a nonapeptide produced by the thymic epithelium originally isolated from
serum, hence its former name, "facteur thymique srique" (7,8). It induces or enhances the
expression of a number of T-cell markers and functions, notably the Thy-1 differentiation antigen
(9).
The aminoacid sequence of this peptide was established (Pyro-Glu-Ala-Lys-Ser-GIn-Gly-
Gly-Ser-Asn), and on the basis of this sequence a biologically active synthetic peptide was obtained
(10). However, some synthetic preparations were surprisingly unstable or inactive, thus suggesting
the need for a posttranslational phenomenon in the expression of the biologically active molecule.
Actually, a number of findings described below demonstrated that the binding of some metals and
particularly zinc is implicated in the biological activity of thymulin.
Several approaches were developed in our laboratory to seek the presence of a transition
metal in the biologically active form of thymulin.
3.1.1. Effect of .c.helex treatment and metal salt addition upon the biological activity of thymulin
We first observed that synthetic or natural thymulin lost its biological activity after treatment
with a chelating agent such as chelex 100, and that this activity was completely restored by the
addition of ZnCI2 or to a lesser extent, of some other metals (galium, aluminium and copper).
Moreover, we noted that the highest degree of activation was achieved when thymulin was mixed
with zinc in an equimolecular ratio. These experiments thus represented the first evidence for the
existence of a thymulin-metal complex. This interaction was further confirmed by gel
chromatography using a mixture of radioactively labeled thymulin and ZnCI2 (11 ).
3.1.2. Physicochemical parameters for zinc-thymulin binding
The affinity, the numbers of binding sites and the relative specificity of zinc binding to
thymulin were established by equilibrium gel chromatography (12). We demonstrated that at pH 7.5
thymulin presented 1 + 0.2 binding site for zinc with an apparent dissociation constant in the order
of 5 + 2.10"7M.
Interestingly, at this same pH, some other metals, particularly gallium and aluminium,
competed with zinc for binding to thymulin, actually conferring biological activity to the peptide. In
addition, structural analogues of thymulin were used to determine which aminoacids were present
in the zinc-binding site of thymulin. The data obtained allowed us to establish the importance of
asparagine, and the role of a particular peptidic bound (between the aminoacid residues 5 and 6) in
thymulin sequence. As detailed below, these findings were confirmed and extended by nuclear
magnetic resonance (NMR) studies.
3.1.3, Conformetional characteristics of thvmulin determined by NMR
Preliminary studies were performed on the metal free peptide (in DMSO solution and in
aqueous medium) using one or two dimensional 1H, 13C NMR and circular dichroism. These
studies strongly suggested that the free nonapeptide in aqueous solution is flexible and in rapid
equilibrum between multiple conformations. In DMSO-d6, thymulin adopted a partially folded
conformation stabilized by three intramolecular hydrogen bounds (13). In view of these results,
similar studies were performed on the thymulin-zinc complex. These experiments clearly indicated
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the existence of two different complexes associating zinc and thymulin, in respective ratios of 1:1
and 1:2. Moreover, we showed that, for the 1:1 complex, the Asn9 as well as the Ser4 and 8
residues were involved in zinc binding (Figure 1). These results were confirmed by the analysis of
some thymulin analogues(14). Since as mentioned above, the complexes containing aluminium,
gallium and to a lesser extent copper have proved to be biologically active, studies of other metal
complexes of the nonapeptide were performed. These studies demonstrated that the changes
induced by the addition of zinc were quite different from those observed with other metal salts
suggesting that the coordination of each ion induced a unique conformation (15,16).
Fig. 1 Schematic representation of the 1"1 zinc-nonapeptide complex showing the Ser4-OH, Ser8-
OH and Asng-CO2 sites coordinated to the metal ions.
3.1.4. Zinc-dependent epitope on the molecule of thymulin
In the past few years, we produced monoclonal antibodies (MAb) directed against synthetic
or natural (intracellular) thymulin (17,18). Both kinds of antithymulin MAb were screened for their
ability a) to inhibit the activity of synthetic or seric thymulin in the rosette assay routinely used to
measure thymulin biological activity, and b) to bind specifically to thymic epithelial cells (TEC) in an
immunofluorescence assay.
More recently, we observed that these MAb recognized the thymulin molecule only if it was
coupled with zinc (19). Thus, for example, when synthetic or seric thymulin was subjected to a
chelation procedure, it was no longer detectable by the antibodies in either the rosette or the
immunofluorescence assay.
However, when zinc was added in an equimolecular ratio to the chelated peptide, the anti-
thymulin MAb were again able to bind to the hormone. These data confirmed that the presence of
zinc in the molecule of thymulin determines a spatial conformation which, in addition to being
necessary to its biological activity, yields a new epitope that can be specifically recognized by
monoclonal antibodies. This epitope is strictly dependent upon the presence of zinc and not of
other metals, such as AI or Cu, which are able to confer the biological activity to the peptide but form
with it complexes not recognized by the monoclonal antibodies (19). These comparative studies
suggested that the 1:1 zinc-thymulin complex was responsible for the specific recognition of the
thymic hormone by monoclonal antibodies.
3.2. Demonstration of the presence of zinc within the thymus
Direct evidence for the presence of zinc within the thymus has come from our previous
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observations using electron microprobe analysis on ultrathin sections of mouse thymus. This
technique allowed us to detect zinc inside cytoplasmic vacuoles of TEC, and further experiments
demonstrated that this metal can be accumulated within these subcellular structures in thymuses
from mice previously injected with zinc chloride (20). These vacuoles were also shown to contain
thymulin.
These data clearly indicated that zinc could be stored within TEC by some specific
mechanism. One hypothetical candidate for the role in the intra-thymic storage of zinc could be
metallothionein. This low molecular weight protein has a high cysteine content and is known to
bind, with high avidity, class II B transitional metals, namely zinc, cadmium and copper (21).
Moreover, it had been previously shown that it is highly expressed in cells that can store zinc (22).
These findings led us to look for metallothionein within the thymus, and we demonstrated by
immunocytochemical means the presence of this protein in TEC both in vivo and in vitro (23). A
closer relationship between metallothionein, zinc and thymulin was established by in vitro
experiments showing that zinc-loaded metallothionein released zinc which was eventually trapped
by thymulin. In this respect our findings support the notion that metallothionein can function as a
zinc acceptor/donor.
4. ZINC DEFICIENCY, ZINC SUPPLEMENTATION AND THYMULIN
4.1. Experimental zinc deprivation
The zinc/thymulin relationship was further investigated in our laboratory using two models
of in vivo zinc deprivation. First, active thymulin levels were studied in sera from mice subjected to a
long-term, marginally zinc-deficient diet. Despite the absence of thymic atrophy, a significant
decrease in the serum levels of thymulin was observed as early as two months after beginning the
diet. However, these levels were consistently restored after in vitro addition of ZnCI2 (5-6). These
findings strongly suggest that the non-active zinc-deprived peptide is secreted in these
experimental conditions. Interestingly, analysis of thymuses from Zn-deprived mice showed that, in
spite of the absence of major changes in thymic epithelial cells, there was a progressive increase in
the number of thymulin-containing cells, suggesting an increase in the production of the hormone.
These observations indicate a compensatory phenomenon, similar to the classical feedback
response already described for thymulin secretion (24). In the case of marginal Zn deficiency, this
feedback effect could be stimulated by the decline of the hormone in its active form, suggesting
that the biological regulatory system recognizes only the peptide containing zinc. This hypothesis is
in agreement with the fact that all the thymulin functions investigated to date require the presence
of zinc in the molecule.
More recently, we made similar observations in human volunteers submitted to zinc-
deficient diets. Their thymulin levels, which were in a normal range at the beginning of the diet,
dropped very rapidly during zinc deprivation, in close parallel with zinc plasma levels, and were
restored to normal after in vivo zinc repletion. In addition, the low thymulin levels observed during
zinc deprivation were also restored to normal values by in vitro addition of zinc chloride (25). These
results represent a further argument in favor of natural coexistence of the active (zinc containing)
and inactive (zinc-deprived) forms of thymulin in the serum, the latter being predominant in zinc-
deficient conditions.
4.2. Effect of oral zinc supplementation in aging mice
The physiological age-dependent decline of thymulin serum levels has already been
extensively described (26,27). As we first demonstrated in 1972, the serum level of this hormone is
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maximal at birth, remains constant until the age of 15 to 20 years and then declines progressively, a
finding which has been confirmed by other investigators (28,29). This phenomenon does not seem
to be restricted to thymulin. Accumulating evidence shows that the circulating levels of other well
defined thymic hormones such a thymopoietin and thymosin (1 also decrease as a function of age.
The studies of thymuses from mice of different ages showed that in normal animals the age-
dependent decline of thymulin in the serum is paralleled by a decrease in the number of thymulin
containing cells, measured by immunofluorescence with anti-thymulin monoclonal antibodies (27).
These data indicated that the diminished levels of circulating thymulin observed in aging are due, at
least partially, to a primary decreased production of the hormone within the thymus.
However, some recent observations suggested that age-related thymic dysfunction and in
particular thymic hypotrophy were not totally irreversible phenomena but could be secondary to
environmental alterations such as zinc deficiency.
We and 3ther groups have been prompted to study the effect of oral zinc supplementation
on some immune parameters in old mice. On the basis of findings that a critical trace element, zinc,
is required for a considerable number of physiological functions in differentiation and proliferation of
cell lineages and synthesis and release of molecules with enzymatic and hormonal action, and that
modification of zinc turnover has been reported to occur with advancing age. Muzzuioli et al. (30)
showed that zinc supplementation in old mice induced regrowth of thymic tissue with reenlargment
of the cortex and recovery of its endocrine activity as measured by the plasma level of thymulin, and
by the number of thymic hormone secreting cells in thymic medulla. At the peripheral level an
increased proportion of Thy 1.2+ and Lytl+ cells in the spleen and partial recovery of PHA
response and NK activity was observed after zinc supplementation.
Similar data on immune parameters were obtained in our laboratory (31). These findings
suggest that the age dependent involution of the thymus is largely dependent on the progressive
loss of zinc bioavaibility that occurs which advancing age.
4.3. Zinc deficiency in pathological situations
We and other groups recently studied thymulin levels in various pathological situations with
zinc deficiency the first study was performed in young children with nephrotic syndrome where we
observed low thymulin levels, compared to age-matched subjects. These low levels of thymulin
activity were restored to normal after remission of the disease or after in vitro addition of zinc salts to
the serum under study (32). In addition, we performed similar studies in subjects with sickle cell
anemia. Studies have shown that several parameters of cellular immune function may be altered in
such patients and are related to a zinc deficiency. In these patients, thymulin levels were found to
be significantly lower than in age-matched healthy subjects. However, as previously observed in
human volunteers in whom restricted zinc intake induced a mild specific deficiency of zinc,
paralleled with low thymulin levels, we observed that zinc supplementation or in vitro zinc activation
restored normal thymulin values (25). Similar results have been recently reported in patients with
chronic renal failure and zinc deficiency in which zinc therapy significantly increased zinc-bound
thymulin in children with Down’s syndrome and in patients with type-I diabetes (33-35).
The mechanism of action of zinc in vivo in these various situations is still unclear. In
particular, it is still open to question whether zinc simply activates pre-existing thymulin molecules,
as shown by in vitro studies, or whether it might also increase the production of thymulin by thymic
epithelial cells.
Nevertheless these observations that zinc is required to render thymulin biologically active
suggest that functional thymulin deficiency could contribute significantly to the immune deficiency
induced by lack of zinc intake.
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5. CONCLUSIONS
The bulk of data reported in the last few years and summarized above strongly indicate that
at least part of the multifaceted intrathymic functions of the trace element zinc may occur via the
activation of the thymic hormone thymulin.
As judged by our findings, the zinc/thymulin coupling probably takes place before the
hormone release by thymic epithelial cells. In this context, the mature (zinc-containing) form of the
hormone would be able, immediately after being secreted, to influence surrounding thymocytes
through its zinc-dependent active site.
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